Evidence map›Paper›PMID 33255517›Full record

ArticleMolecules (Basel, Switzerland)2020

In Silico Design of a Peptide Receptor for Dopamine Recognition.

Luna Rodriguez-Salazar, James Guevara-Pulido, Andrés Cifuentes

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Luna Rodriguez-SalazarBioingeniería, Universidad El Bosque, Bogotá 110121, Colombia.
James Guevara-PulidoQuímica Farmacéutica, Facultad de Ciencias, Universidad El Bosque, Bogotá 110121, Colombia.ORCID 0000-0001-9134-3719
Andrés CifuentesQuímica Farmacéutica, Facultad de Ciencias, Universidad El Bosque, Bogotá 110121, Colombia.
Universidad El Bosque · CO

Funding

Vicerrectoría de Investigaciones Universidad El Bosque PCI-2017-9646
6 · The paper itself

Abstract

Dopamine (DA) is an important neurotransmitter with a fundamental role in regulatory functions related to the central, peripheral, renal, and hormonal nervous systems. Dopaminergic neurotransmission dysfunctions are commonly associated with several diseases; thus, in situ quantification of DA is a major challenge. To achieve this goal, enzyme-based biosensors have been employed for substrate recognition in the past. However, due to their sensitivity to changes in temperature and pH levels, new peptide bioreceptors have been developed. Therefore, in this study, four bioreceptors were designed in silico to exhibit a higher affinity for DA than the DA transporters (DATs). The design was based on the hot spots of the active sites of crystallized enzyme structures that are physiologically related to DA. The affinities between the chosen targets and designed bioreceptors were calculated using AutoDock Vina. Additionally, the binding free energy, ∆G, of the dopamine-4xp1 complex was calculated by molecular dynamics (MD). This value presented a direct relationship with the E_refine value obtained from molecular docking based on the ∆G functions obtained from MOE of the promising bioreceptors. The control variables in the design were amino acids, bond type, steric volume, stereochemistry, affinity, and interaction distances. As part of the results, three out of the four bioreceptor candidates presented promising values in terms of DA affinity and distance.

Indexed as

Drug DesignMolecular Docking SimulationMolecular Dynamics SimulationAmino Acid SequenceBinding SitesCatalytic DomainDopamineHydrogen BondingLigandsProtein BindingReceptors, PeptideStructure-Activity RelationshipDopamineLigandsReceptors, Peptidebioreceptordopaminein silicomolecular dockingmolecular dynamics

Identifiers

PMID33255517
PMCPMC7727804
OpenAlexW3108943172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.